C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2026)

C4 Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $462000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 1104.35% year-over-year to $462000.0 in Q1 2026; TTM through Mar 2026 was $126.9 million, a 1085.27% increase from a year earlier, with the FY2025 full-year figure at $126.4 million, up 178.8% from the prior year.
• Cash from Financing Activities retreated to $462000.0 in Q1 2026 per CCCC's latest filing, from $118.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $118.7 million in Q4 2025 and bottomed at -$10.8 million in Q3 2023.
• The 5-year median for Cash from Financing Activities is $310000.0 (2022), against an average of $13.7 million.
• Biggest YoY gain for Cash from Financing Activities was 122606.38% in 2023; the steepest drop was 3078.67% in 2023.
• Year by year, Cash from Financing Activities stood at $47000.0 in 2022, then soared by 122606.38% to $57.7 million in 2023, then slumped by 99.81% to $112000.0 in 2024, then surged by 105857.14% to $118.7 million in 2025, then plunged by 99.61% to $462000.0 in 2026.
• Per Business Quant, the three latest CCCC Cash from Financing Activities figures stand at $462000.0 (Q1 2026), $118.7 million (Q4 2025), and $7.8 million (Q3 2025).